Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2019-10-29

FDA Approved: CAMPATH — Supplemental Application (Genzyme Corporation)

View source ↗

Summary

FDA approved a supplemental application for CAMPATH (alemtuzumab) submitted by Genzyme Corporation. The approval updates the labeling/indication for the product…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CAMPATH (ALEMTUZUMAB)

Snippet

SUPPL AP for CAMPATH (ALEMTUZUMAB)